Aktis Oncology, Inc. Common stock Cash Flow-to-Debt Ratio
Aktis Oncology, Inc. Common stock cash flow-to-debt ratio. Aktis Oncology, Inc. Common stock (AKTS) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2024, meaning its operating cash flow of $-12.80 Million could theoretically repay 0% of its total liabilities ($413.98 Million) in one year. See Aktis Oncology, Inc. Common stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aktis Oncology, Inc. Common stock (2014–2024)
Cash flow-to-debt ratio of Aktis Oncology, Inc. Common stock from 2014 to 2024. Historical debt coverage capacity for Aktis Oncology, Inc. Common stock across 21 annual periods. Check Aktis Oncology, Inc. Common stock total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Aktis Oncology, Inc. Common stock Cash Flow-to-Debt Ratio by Year (2014–2024)
Aktis Oncology, Inc. Common stock cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Aktis Oncology, Inc. Common stock. For the full cash flow conversion analysis, see AKTS operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | $14.76 Million | $413.98 Million | ▲ +111.2% |
| 2024 | -0.32x | $-40.35 Million | $126.83 Million | ▼ -78.8% |
| 2023 | -0.18x | $-30.00 Million | $168.66 Million | ▲ +75.1% |
| 2023 | -0.72x | $-44.82 Million | $62.68 Million | ▼ -521.6% |
| 2022 | -0.12x | $-18.12 Million | $157.55 Million | ▲ +85.3% |
| 2022 | -0.78x | $-45.20 Million | $57.91 Million | ▲ +0.0% |
| 2021 | -0.78x | $-45.20 Million | $57.91 Million | ▲ +79.8% |
| 2021 | -3.87x | $-29.36 Million | $7.58 Million | ▼ -444.1% |
| 2020 | -0.71x | $-21.30 Million | $29.94 Million | ▲ +0.0% |
| 2020 | -0.71x | $-21.30 Million | $29.94 Million | ▲ +11.4% |
| 2019 | -0.80x | $-17.67 Million | $21.99 Million | ▲ +0.0% |
| 2019 | -0.80x | $-17.67 Million | $21.99 Million | ▲ +12.6% |
| 2018 | -0.92x | $-14.20 Million | $15.46 Million | ▲ +0.0% |
| 2018 | -0.92x | $-14.20 Million | $15.46 Million | ▲ +49.0% |
| 2017 | -1.80x | $-5.55 Million | $3.08 Million | ▲ +0.0% |
| 2017 | -1.80x | $-5.55 Million | $3.08 Million | ▼ -205.4% |
| 2016 | -0.59x | $-1.10 Million | $1.87 Million | ▲ +0.0% |
| 2015 | -0.59x | $-1.10 Million | $1.87 Million | ▲ +80.3% |
| 2015 | -2.99x | $-980.04K | $327.66K | ▲ +0.0% |
| 2014 | -2.99x | $-980.04K | $327.66K | ▲ +96.6% |
| 2014 | -88.17x | $-26.98K | $306.00 | — |